In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...

The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...

More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...

WASHINGTON, DC—In women with symptomatic severe aortic stenosis (AS), TAVI yields better outcomes at 1 year compared with surgery, with no differences by annular size or age, according to a large ...

Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the ...

DUBLIN, Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, ...

Medtronic plc presented 10-year results from its ongoing trial comparing transcatheter aortic valve implantation with surgical aortic valve replacement. The results support use of the Medtronic ...

Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the ...

Clinical suitability is the primary requirement for selection of a patient for TAVI. Although TAVI compares favorably to conservative treatment in patients at high risk of or inoperable by ...

Abbott ABT recently announced significant progress with Navitor, the company’s latest-generation transcatheter aortic valve implantation (TAVI) system. The company announced late-breaking data for ...